Premium
Prenatal diagnosis of atrial restriction in hypoplastic left heart syndrome is associated with decreased 2‐year survival
Author(s) -
Lowenthal Alexander,
Kipps Alaina K.,
Brook Michael M.,
Meadows Jeffery,
Azakie Anthony,
MoonGrady Anita J.
Publication year - 2012
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.3850
Subject(s) - hypoplastic left heart syndrome , medicine , cardiology , retrospective cohort study , heart disease , survival rate , surgery
Objective To compare the course of hypoplastic left heart syndrome (HLHS) patients diagnosed prenatally with any degree of atrial restriction with those without evidence of atrial restriction. Design Retrospective, cohort. Methods Prenatally diagnosed HLHS patients from August 1999 to January 2009 were categorized as nonrestrictive versus restrictive, defined by left atrial hypertension on pulmonary venous Doppler and/or an intact interatrial septum. Results Of 73 total fetal patients identified, 49 were live‐born. Survival at 2 years was 29/35 [83% confidence interval (CI): 59.5%–88.9%] for the nonrestrictive group and 6/14 (43% CI: 17.7%–6.0%) for the restrictive group ( p < 0.0001). Of those who underwent stage 1 palliation (35 with nonrestrictive and 10 with restrictive atrial septa), both groups had a similar incidence of preoperative acidosis and need for ventilation and inotropic support. Postoperatively, there was no difference between groups in ventilator days, length of stay, or survival to discharge. There was decreased survival at 2 years in the restrictive group, 60% (CI: 26.2%–87.8%) versus 83% (CI: 66.4%–93.4%) in the nonrestrictive group. Furthermore, a disproportionate number of interstage deaths was evident in the restrictive group. Conclusions Prenatal presence of any degree of atrial septal restriction in the setting of HLHS confers a significant survival disadvantage, with increases in both early and late mortality. © 2012 John Wiley & Sons, Ltd.